Rigel Pharmaceuticals
RIGL
117 hedge funds and large institutions have $164M invested in Rigel Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 38 reducing their positions, and 12 closing their positions.
1,976% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $50K
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
4% more funds holding
Funds holding: 112 → 117 (+5)
0.61% less ownership
Funds ownership: 6.94% → 6.33% (-0.61%)
8% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 38
7% less capital invested
Capital invested by funds: $176M → $164M (-$11.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.83M |
| 2 |
Millennium Management
New York
|
+$1.48M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.4M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.14M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$19.5M |
| 2 |
AC
Armistice Capital
New York
|
-$2.34M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.78M |
| 4 |
BlackRock
New York
|
-$538K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$532K |
RIGL Hedge Fund Activity: Q1 2024 in Review
117 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2024, worth a combined $164M — down 6.7% from $176M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 38 trimmed.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $1.83M. The largest seller was Morgan Stanley, cutting an estimated $19.5M.
- 117 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2024, up from 112 in Q4 2023.
- Funds reported $164M of Rigel Pharmaceuticals stock for Q1 2024, down 6.7% quarter-over-quarter.
- 17 funds opened new Rigel Pharmaceuticals positions in Q1 2024 and 12 closed out, a net change of +5 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2024 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.83M added.
- The largest Rigel Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $19.5M sold.
Based on aggregated 13F filings for Q1 2024.